CN110896606B - 用于治疗自身免疫性水疱病的coversin - Google Patents

用于治疗自身免疫性水疱病的coversin Download PDF

Info

Publication number
CN110896606B
CN110896606B CN201880041710.5A CN201880041710A CN110896606B CN 110896606 B CN110896606 B CN 110896606B CN 201880041710 A CN201880041710 A CN 201880041710A CN 110896606 B CN110896606 B CN 110896606B
Authority
CN
China
Prior art keywords
coversin
seq
aibd
protein
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880041710.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN110896606A (zh
Inventor
迈尔斯·安德鲁·纳恩
B·阿比扬卡
C·D·萨迪克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Volution Immuno Pharmaceuticals SA
Original Assignee
Volution Immuno Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1706404.9A external-priority patent/GB201706404D0/en
Priority claimed from GBGB1706406.4A external-priority patent/GB201706406D0/en
Priority claimed from GBGB1706452.8A external-priority patent/GB201706452D0/en
Application filed by Volution Immuno Pharmaceuticals SA filed Critical Volution Immuno Pharmaceuticals SA
Publication of CN110896606A publication Critical patent/CN110896606A/zh
Application granted granted Critical
Publication of CN110896606B publication Critical patent/CN110896606B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Transplantation (AREA)
CN201880041710.5A 2017-04-21 2018-04-20 用于治疗自身免疫性水疱病的coversin Active CN110896606B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1706404.9 2017-04-21
GBGB1706404.9A GB201706404D0 (en) 2017-04-21 2017-04-21 Method of treatment
GB1706406.4 2017-04-21
GBGB1706406.4A GB201706406D0 (en) 2017-04-21 2017-04-21 Method of treatment
GB1706452.8 2017-04-24
GBGB1706452.8A GB201706452D0 (en) 2017-04-24 2017-04-24 Method of treatment
PCT/EP2018/060241 WO2018193122A1 (en) 2017-04-21 2018-04-20 Coversin for the treatment of autoimmune blistering diseases

Publications (2)

Publication Number Publication Date
CN110896606A CN110896606A (zh) 2020-03-20
CN110896606B true CN110896606B (zh) 2024-07-16

Family

ID=62235916

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880041710.5A Active CN110896606B (zh) 2017-04-21 2018-04-20 用于治疗自身免疫性水疱病的coversin

Country Status (12)

Country Link
US (2) US11730792B2 (enExample)
EP (2) EP3612208B1 (enExample)
JP (2) JP7209637B2 (enExample)
KR (1) KR102656199B1 (enExample)
CN (1) CN110896606B (enExample)
AU (1) AU2018253962B2 (enExample)
CA (1) CA3059657A1 (enExample)
DK (1) DK3612208T5 (enExample)
ES (1) ES2945433T3 (enExample)
IL (1) IL269895B2 (enExample)
PL (1) PL3612208T3 (enExample)
WO (1) WO2018193122A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410116D0 (en) 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
GB201706406D0 (en) 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
EP3612206A1 (en) * 2017-04-21 2020-02-26 Volution Immuno Pharmaceuticals SA Coversin for the treatment of cicatrising eye inflammatory disorders
IL269895B2 (en) 2017-04-21 2024-06-01 Volution Immuno Pharmaceuticals Sa Coversin for the treatment of autoimmune blistering diseases
US20220047673A1 (en) * 2018-09-10 2022-02-17 Volution Immuno Pharmaceuticals Sa Coversin for Use in the Treatment of Rheumatic Diseases
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
US20220370556A1 (en) 2019-09-27 2022-11-24 Volution Immuno Pharmaceuticals Sa Method of Treatment
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102341407A (zh) * 2009-02-05 2012-02-01 自然环境研究会 作为补体抑制剂的经修饰的omci

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
WO2004106369A2 (en) 2003-06-02 2004-12-09 Evolutec Limited Complement inhibitors from ticks
EP1739078A1 (de) 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
WO2007095230A2 (en) 2006-02-13 2007-08-23 The Trustees Of The University Of Pennsylvania TREATMENT OF AUTOIMMUNE BLISTERING DISEASE USING ANTI-IgE ANTIBODY
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
WO2008029169A2 (en) 2006-09-08 2008-03-13 Varleigh Limited Method of treating respiratory disorders
CN101679486A (zh) 2007-03-22 2010-03-24 诺瓦提斯公司 C5抗原及其用途
EA021222B8 (ru) * 2007-06-21 2015-11-30 ИксЭль-ПРОТЕИН ГМБХ Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
AU2009302473A1 (en) * 2008-10-06 2010-04-15 Carolus Therapeutics, Inc. Methods of treating inflammation
CN102597005A (zh) * 2009-06-23 2012-07-18 阿雷克森制药公司 与补体蛋白质结合的双特异性抗体
US9290736B2 (en) * 2009-11-04 2016-03-22 Case Western Reserve University Compositions and methods of treating T cell mediated disorder
NZ601018A (en) 2010-01-08 2013-09-27 Varleigh Immuno Pharmaceuticals Ltd Ev576 for use in the treatment of viral infections of the respiratory tract
BR112013033272A2 (pt) 2011-06-22 2020-11-10 Apellis Pharmaceuticals, Inc. composição farmaceutica compreendendo um inibidor do complemento e um agente anti-th17, e usos dos mesmos
TW201418707A (zh) 2012-09-21 2014-05-16 Alexion Pharma Inc 補體組分ｃ５拮抗劑之篩選分析
ES2768648T3 (es) * 2013-03-29 2020-06-23 Alexion Pharma Inc Composiciones y métodos para aumentar la semivida en suero de un agente terapéutico dirigido a C5 del complemento
GB201410031D0 (en) 2014-06-05 2014-07-16 Isis Innovation Polypeptides and uses thereof
WO2016198133A1 (en) 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
GB201410116D0 (en) 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
US20160168237A1 (en) * 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
RS62630B9 (sr) * 2015-01-28 2022-04-29 Ra Pharmaceuticals Inc Modulatori aktivnosti komplementa
WO2016200627A1 (en) * 2015-06-09 2016-12-15 Children's Hospital Medical Center Dosing algorithm for complement inhibitor
EP4365291A3 (en) * 2015-06-12 2024-08-14 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
EP3328885A1 (en) * 2015-09-11 2018-06-06 Bruce Andrien Recombinant glycosylated eculizumab and eculizumab variants
GB201706406D0 (en) 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
EP3612206A1 (en) 2017-04-21 2020-02-26 Volution Immuno Pharmaceuticals SA Coversin for the treatment of cicatrising eye inflammatory disorders
IL269895B2 (en) 2017-04-21 2024-06-01 Volution Immuno Pharmaceuticals Sa Coversin for the treatment of autoimmune blistering diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102341407A (zh) * 2009-02-05 2012-02-01 自然环境研究会 作为补体抑制剂的经修饰的omci

Also Published As

Publication number Publication date
JP2020517627A (ja) 2020-06-18
KR102656199B1 (ko) 2024-04-09
IL269895B1 (en) 2024-02-01
EP3612208A1 (en) 2020-02-26
KR20190139233A (ko) 2019-12-17
PL3612208T3 (pl) 2023-07-24
JP2023040169A (ja) 2023-03-22
EP4275696A1 (en) 2023-11-15
CA3059657A1 (en) 2018-10-25
IL269895B2 (en) 2024-06-01
JP7600278B2 (ja) 2024-12-16
DK3612208T5 (da) 2024-09-02
CN110896606A (zh) 2020-03-20
ES2945433T3 (es) 2023-07-03
US20240009270A1 (en) 2024-01-11
JP7209637B2 (ja) 2023-01-20
AU2018253962B2 (en) 2024-12-05
US20200113971A1 (en) 2020-04-16
WO2018193122A1 (en) 2018-10-25
AU2018253962A1 (en) 2019-10-31
DK3612208T3 (da) 2023-05-08
IL269895A (enExample) 2019-12-31
EP3612208B1 (en) 2023-04-05
US11730792B2 (en) 2023-08-22

Similar Documents

Publication Publication Date Title
CN110896606B (zh) 用于治疗自身免疫性水疱病的coversin
TWI784988B (zh) 治療發炎症狀的方法
CN106659767B (zh) 用于治疗具有c5多态性的患者的补体介导的疾病的毛白钝缘蜱补体抑制剂
EP3612207B1 (en) Coversin variants lacking c5 binding
JP7153669B2 (ja) 瘢痕性眼炎症障害の治療のためのコバーシン
AU2019468121A1 (en) Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA)
CN114072206B (zh) 治疗方法
JP7629394B2 (ja) リウマチ性疾患の治療に使用するためのコバーシン
JP7511551B2 (ja) 改変されたＭＨＣクラスＩＩ ＤＲα１ドメインを含む組換えポリペプチドおよび使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant